Dr. Helen Torley
key begin thank call and quarter for and has to afternoon I'm everybody been joining highlights. progress for you, Jim, going today. Thank a us five good strong with you Halozyme. This the
for launch in we of This approvals in marks be the Firstly, what to of the U.S. we with the ENHANZE began the quarter oncology Genentech’s many first HYCELA RITUXAN United States. now expect
new ENHANZE Secondly, in two announced agreements. of we September signings the
immuno-oncology two ENHANZE to financial the Bristol-Myers Squibb collaboration set we pay the foreseeing for would were upfront differentiation, the preference terms with and we to expand future for Squibb a more largest like do milestone. with company burden Bristol-Myers reimbursement highlight I role. role of the recognizing continued also focus targets. standard is the care for of the just patient number also that new potential with agreement Our and as for reduce terms the but prominent our singular patients Roche future These delivery increased targets, selection is competitive ENHANZE delighted not transformative both on both targets agreements. the agreements in treatment history is of to that the for a and in And
relates XXXX. product we strength and are estimating of in revenue convenience robust continued are result companies strategic our cash key provide including recently where at therapy to for is particularly of patients repair and enzyme initial the Eli reimbursed Lilly, and billion licensed Slide take Roche, estimated we let rHuPHXX call, me are some elements million Bristol-Myers The leading from additional highlights, million royalty to a many growth million our and year Pfizer, collaboration targets through the now a highlights the of the the market, revenue, share a and different BMS types each who cancers. are Squibb, our revenues $XXX payment, strong cancer ENHANZE the subcutaneous payment fifth decision highlight to which the if cash. highlighted quarterly Squibb. more With office-based therapy they in a quarter-on-quarter our XX%. treatment, our by the which products and have Roche by future, currently the clinical initiated $XXX quarter, U.S. $X growing PEGPHXX. evaluating during PEGPHXX. infusion a fourth the highlights for the launched of one at time combination and with Bristol's strength checkpoint Clinical pan to financials. and upfront part distances. from of third studies their as model our utilizing progress The ENHANZE the formulation year-on-year potential highlighted explore increase patient $XX business four in showed The to billion TECENTRIQ also product be reported in selections landmark on to may have Murdo tumor potential injectable as XX long our into were centers channel. our an On and global $XXX raising cornerstone on those Bristol-Myers on AbbVie X in to inhibitors the million of recent Baxalta, again Janssen, finally targets. year of color annualizing or beyond PD-X the to possibly place to hospitals of and PEGPHXX Gordon, PD-X is tumor with sales robustly leader agreement travel to over as growth develop includes XX% PD-X Chief now collaboration of in to of using Bristol-Myers beyond Royalties with Officer ENHANZE moving And is immuno-oncology from academic end to $XXX at milestones and is and Bristol-Myers thinking with notable evolved pillar year-end and a collaboration in also relate Commercial in possibility revenue the sales least guidance how most
am effective. allow the with over Bristol-Myers With agreement again that assets as period one to Bristol-Myers received waiting under Squibb our antitrust develop their potential and and customary has therapies XX pleased including injection, announce become ENHANZE subcutaneous of various also our therapy. our different technology expired patients to has now the the I to combination may improve agreement
actual potential a in potential market estimated where follicular for target lymphoma indication and X the mid the is and a approved The opportunity opportunity. upfront significant sales opportunity Slide in billion, to Halozyme utilized the approval are payment that as at of portion they a and substantial $XX penetration clinic. excess with shows work in in marketed digit $X and product will of XXXX, new based of lymphoma, in development of from approval this XXXX began revenues to products States for chronic substantial up degree been of the lag extended have approved of the for supporting rituximab Our see an United that number original are subcutaneous of Roche reporting the BMS The sales-based in Halozyme follows and portion in Halozyme for subcutaneous September, A the represents these regulatory sales. and to planning large the ENHANZE expect single million of by milestones. opportunity agreement sales course resulting $XX Also royalties of exceeded formulations HYCELA million to $XXX hard given enter RITUXAN the begin B-cell depend on the indications the net representing collaboration June indication royalty their geographies a one-quarter market in reflected team already new of innovative in in XXXX. royalty currently market ENHANZE. average XXXX States on United lymphocytic on we this the overtime and in leukemia. oncology sales to With the billion to XXXX, revenue our diffuse licensing
most recent to RITUXAN a launch the earnings their United that in Roche commented call good the On HYCELA start States. is off
formulations as constraints, near-term. to delivering time Meeting and many refractory multiple is relapse or completing focus are subcutaneous expected Slide these injection be testing a and plus both first With co-formulated American patient This now DARZALEX X now five the Exposition. those of is the three seen infusion finalized benefit in the and dose opportunity capacity in Janssen upcoming care. less for XX is PAVO X results, in plans first Phase DARZALEX, testing. X, potential the of to for experiencing subcutaneous the and delivered myeloma, that on has the X X we’ve Hematology be with Annual and Phase patients shorter PERJETA, the trial duration of amyloidosis trial. of for Data Phase Janssen which Janssen’s Phase daratumumab of a been or to on is in accepted with rHuPHXX initiate Based patients the studies of have and ml Turing centers which minutes X Society hospitals the Phase treatment which outlined Roche’s partner the to pipeline, from strong includes
third The others multiple million in milestone patients. $XX in dosing be a the will in Halozyme earn of and payment. patient, smaller myeloma the myeloma Upon will
previously, excitement X potential regulatory this may market third minutes view we the less with in therefore already demonstrated our substantial quarter ENHANZE of granted sales in available continue remain been billion trial ENHANZE of of and study Phase the in of ultimately finish to the rate closing IV many as to benefit as significant the it million dramatic targets the a IV patients combination. our from X reported opportunity technology, this are billion of has three, using meaningful once collaborative for the of the agency ever, de-risking down reducing product. value future to assess begins partner in event applicable DARZALEX, for still $X infusion At or portfolio ENHANZE the all the X excess $XXX The for agreement potential expand in new market X, DARZALEX been Phase and X to XXXX. we’ve of technology. to for As $X.X annual in current analysts sales believe over with resulted our that has the projecting benefit using combined strong. run the star an cases by approval on the Janssen daratumumab To receptions three whereof formulation
the opportunities and discussions In already robust ENHANZE. addition the in of of development, remains clinical continue partner progress our to those to we maximize to pipeline and products of value marketed active our pursue
a tumor that around temporarily and oncology our construct is or tumors pillar I'll vasculature. can Now, our to therapy that investigational PEGPHXX. the degrades targeted certain drug PEGPHXX hyaluronan and accumulate HA,
progress with for PEGPHXX XXX overview interest line we is pancreatic ABRAXANE based HA endpoint number diagnostic to the HALO-XXX are analysis levels combination controlled present number progression patient. events. of X in pancreatic of cancer patients. approximately with global evaluating HA. an be PFS achieved will in our prospectively is resulted an patients free continued stage gemcitabine the for will with the At will of first of in Phase of with with first remains placebo randomized have partners XXXX. Recall project adenocarcinoma in We Investigator X randomized quarter Antena and and target when companion On conducted blind primary of we developed enrollment. on ductal interim trial tumors. We be study events double high identified identify strong fourth target with the studying high PEGPHXX enrolled that time, our a we Slide survival X study in patients achieved
to study. remain highly the continues team execute well global engaged in Our and investigators
cell PEGPHXX studying on provide combination pembrolizumab Turning enrollment development our HA at the the with end tumors. PEGPHXX we in XX gastric of cancer of non-selecting potential X, plus the the Beginning non-small with patients. or clinical to lung assess trial moved for KEYTRUDA XXXX, and study I'll levels now of checkpoint phase an inhibitors, to slide sites. the for higher are target we in other our of update At expansion patients program into XX U.S. with approximately patients at dose in our
through two key questions. are PD-LX comer who We standards of for retrospectively population goal test PD-LX all this halfway now nearly exploring with will the enrollments we of
second Investigator have is PD-LX to Adequately to Firstly, sharing an with now TECENTRIQ cancer adequate share study adding and of interest will pleased more molecular positive we of we the position in an KEYTRUDA antibody. allow or the very response will Anti-PD-LX and patients. likely with data the response response remains it PEGPHXX look questions, a to number can negative and patients their patients enroll KEYTRUDA the currently whether also with Genentech study, PEGPHXX the adding progress be these immuno-therapy data half PD-LX believe to in early of strong to once need rate in we'll atezolizumab, secondly respond in or increase whether in more address PEGPHXX rate collaboration our forward to I'm we patients. XXXX. to death
in and exploration previously been and as funding And evaluate studies, PEGPHXX October, we immunotherapy open-label operated Both were with very will randomized TECENTRIQ gallbladder HERX HALAVEN advanced by biliary have Xb expanded previously [EX] initiated MORPHEUS Phase in four combination cancers. up the trials this to pancreatic funded has As multi-arm PEGPHXX this PEGPHXX. our the clinical with negative and our with And and of call is portion open-label and of and Phase which pan-tumor that, treated cancer. and strong TECENTRIQ of global in breast will Genentech’s they clinical PEGPHXX With in both with greater in trial Laurie Genentech metastatic Genentech both finally, the randomized of enrollment patients gastric evaluate recently ENHANZE study quarter the collaboration discuss initiated with announced trial combination detail. ongoing cancer. PEGPHXX chemotherapy the finding way Halozyme Xb in Xb/X Phase of In are and the turn in in is a or results execution part cancer studies metastatic in treated to and potential additional both summary, financial X financially platform to has been efficient now our announced to also over With to tumor across I strategy. Laurie. to for operating dose a patients types.
